- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Vamorolone 0.25 mg/day/day, Vamorolone 0.75 mg/day/day, Vamorolone 2.0 mg/day/day, Vamorolone 6.0 mg/day/day
- Drug
- Lead sponsor
- ReveraGen BioPharma, Inc.
- Industry
- Eligibility
- 4 Years to 7 Years · Male only
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 6
- States / cities
- Davis, California • Gainesville, Florida • Orlando, Florida + 3 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–7
of 7
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Vamorolone, Prednisone, Placebo
- Drug · Other
- Lead sponsor
- ReveraGen BioPharma, Inc.
- Industry
- Eligibility
- 4 Years to 7 Years · Male only
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 10
- States / cities
- Davis, California • Los Angeles, California • Aurora, Colorado + 7 more
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Vamorolone
- Drug
- Lead sponsor
- Santhera Pharmaceuticals
- Industry
- Eligibility
- Male only
- U.S. locations
- 6
- States / cities
- Davis, California • Orlando, Florida • Chicago, Illinois + 3 more
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Vamorolone 0.25 mg/kg/day, Vamorolone 0.75 mg/kg/day, Vamorolone 2.0 mg/kg/day, Vamorolone 6.0 mg/kg/day
- Drug
- Lead sponsor
- ReveraGen BioPharma, Inc.
- Industry
- Eligibility
- 4 Years to 6 Years · Male only
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 6
- States / cities
- Davis, California • Gainesville, Florida • Orlando, Florida + 3 more
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Vamorolone 0.25 mg/day/day, Vamorolone 0.75 mg/day/day, Vamorolone 2.0 mg/day/day, Vamorolone 6.0 mg/day/day
- Drug
- Lead sponsor
- ReveraGen BioPharma, Inc.
- Industry
- Eligibility
- 4 Years to 7 Years · Male only
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 6
- States / cities
- Davis, California • Gainesville, Florida • Orlando, Florida + 3 more
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Vamorolone
- Drug
- Lead sponsor
- Catalyst Pharmaceuticals, Inc.
- Industry
- Eligibility
- 2 Years and older · Male only
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2032
- U.S. locations
- 31
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • Loma Linda, California + 27 more
- Conditions
- Becker Muscular Dystrophy
- Interventions
- Vamorolone, Placebo
- Drug
- Lead sponsor
- ReveraGen BioPharma, Inc.
- Industry
- Eligibility
- 18 Years to 64 Years · Male only
- Enrollment
- 46 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Pittsburgh, Pennsylvania